TerminatedPhase 1psilocybin

Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Sponsored by Beckley Psytech Limited

NCT ID
NCT04905121
Target Enrollment
4 participants
Start Date
2021-08-11
Est. Completion
2022-04-22

About This Study

This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Conditions Studied

Short Lasting Unilateral Neuralgiform Headache Attacks

Interventions

  • •Psilocybin

Eligibility

Age:18 Years - 80 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

\* Diagnosed with chronic SUNHA

Exclusion Criteria:

\* Other comorbidities

Study Locations (1)

King's College London
London, United Kingdom

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) | Huxley